Member Info for TRENCH123

The company have been in a transition period away from total reliance on oncology and the breadth of work they now undertake has given it a much wider network of opportunities. PYC is a changed business from even 12 months ago with some excellent appointments including Dr Jesse Thissen who has made a very promising start as Head of Biometrics and Dr Mark Davies as Head of Quantitative Pharmacology and the addition of some quality new partners. I believe that the patience of long-term investors will pay off here and a transformed business will emerge. Obviously potential investors need to do their own detailed homework and make their own assessment, independent of the embedded positive and negative viewpoints expressed here

I expect that the contracts will be profitable individually and contribute towards the company overheads. The problem in the past has been insufficient volume and hence contributions to cover those overheads. The company growth policy should clearly improve this situation with a move closer to profitability. That is why all new contract announcements are to be welcomed IMHO

This collaboration marks a further expansion of our work into infectious disease and an important step for our growing Biometrics capability. We’re looking forward to combining our in-house expertise with our wider consultant network to support this programme.

A strong way to close the year, and an exciting area to be contributing our expertise.

Sorry, but that is my honest opinion

It is a share chat board and quite rightly there are views from all ends of the spectrum which can be openly challenged. In the end people must take time and use their own judgment in any investment decisions they make and take ownership of them

Burt lost money here and blamed no one but himself. He was a great example of how investors should behave when they unfortunately lose out

I see nowhere where Laura has mentioned to invest for three hours and then sell

The £100k + contract is good news. The move away from total reliance on oncology-related work is opening up some excellent opportunities here

Booking contracts well into the future and growing. I take a completely different perspective on things, rightly or wrongly.

Thanks Laura. Yes I have seen KingH's in depth analysis which shows a real potential for re-rate here

Must be close to getting some news on the expanded DoseMe partnership. Could be very interesting

Good to see forward contracts being built up. Much better business model in place now

The negative posters here are on a co-ordinated mission to try and bring the company down. They have no interest in the company succeeding, in fact if it was they would be absolutely gutted. The internet has been a bad influence on some peoples outlook on life, making them insular and rebellious

But each to his own I suppose. As they say 'there's nowt so queer as folk'

The Numab contract announced yesterday, covering maybe six months, will be a decent value. In common with previous releases with this client, no value can be specified for confidentiality reasons

Avocet123, you need a job in the Treasury

Further revenue from important partners is to be welcomed. There is no negative here IMHO

Jaari, good to know you are your usual happy self today, reminiscing about times gone by

Resistance to antibiotics is one of the major challenges today and if PYC can help in this area, then what's not to like

Don't worry so much, calm down and relax. Why not read the following issued in conjunction with the IMC meeting just two months ago :-

'Looking ahead, the company entered FY26 with £654k of contracted income already secured, alongside a strong late-stage pipeline of new opportunities. Management will continue to focus on revenue growth, cost control, operational efficiency, and margin improvement while exploring strategic M&A or partnerships to accelerate scale. With growing demand for model-informed drug development, biometrics, and personalised medicine, Physiomics is positioned in high-growth markets with projected double-digit CAGR across its service areas. Supported by blue-chip client relationships, increasing diversification, and a robust cash position, the Group is confident in delivering sustainable growth, enhanced profitability, and long-term shareholder value'

..... and some new 'investors' buying in. That's the way the market works

My comments are based on company information in the public domain, recent company presentations made and contact made with the company. This is the best information available to me and I am happy to rely on it

KingH may be best placed to provide some indication